1
|
Mullane KM, Morrison VA, Camacho LH, Arvin A, McNeil SA, Durrand J, Campbell B, Su SC, Chan ISF, Parrino J, Kaplan SS, Popmihajlov Z, Annunziato PW, Cerana S, Dictar MO, Bonvehi P, Tregnaghi JP, Fein L, Ashley D, Singh M, Hayes T, Playford G, Morrissey O, Thaler J, Kuehr T, Greil R, Pecherstorfer M, Duck L, Van Eygen K, Aoun M, De Prijck B, Franke FA, Barrios CHE, Mendes AVA, Serrano SV, Garcia RF, Moore F, Camargo JFC, Pires LA, Alves RS, Radinov A, Oreshkov K, Minchev V, Hubenova AI, Koynova T, Ivanov I, Rabotilova B, Minchev V, Petrov PA, Chilingirov P, Karanikolov S, Raynov J, Grimard D, McNeil S, Kumar D, Larratt LM, Weiss K, Delage R, Diaz-Mitoma FJ, Cano PO, Couture F, Carvajal P, Yepes A, Torres Ulloa R, Fardella P, Caglevic C, Rojas C, Orellana E, Gonzalez P, Acevedo A, Galvez KM, Gonzalez ME, Franco S, Restrepo JG, Rojas CA, Bonilla C, Florez LE, Ospina AV, Manneh R, Zorica R, Vrdoljak DV, Samarzija M, Petruzelka L, Vydra J, Mayer J, Cibula D, Prausova J, Paulson G, Ontaneda M, Palk K, Vahlberg A, Rooneem R, Galtier F, Postil D, Lucht F, Laine F, Launay O, Laurichesse H, Duval X, Cornely OA, Camerer B, Panse J, Zaiss M, Derigs HG, Menzel H, Verbeek M, Georgoulias V, Mavroudis D, Anagnostopoulos A, Terpos E, Cortes D, Umanzor J, Bejarano S, Galeano RW, Wong RSM, Hui P, Pedrazzoli P, Ruggeri L, Aversa F, Bosi A, Gentile G, Rambaldi A, Contu A, Marei L, Abbadi A, Hayajneh W, Kattan J, Farhat F, Chahine G, Rutkauskiene J, Marfil Rivera LJ, Lopez Chuken YA, Franco Villarreal H, Lopez Hernandez J, Blacklock H, Lopez RI, Alvarez R, Gomez AM, Quintana TS, Moreno Larrea MDC, Zorrilla SJ, Alarcon E, Samanez FCA, Caguioa PB, Tiangco BJ, Mora EM, Betancourt-Garcia RD, Hallman-Navarro D, Feliciano-Lopez LJ, Velez-Cortes HA, Cabanillas F, Ganea DE, Ciuleanu TE, Ghizdavescu DG, Miron L, Cebotaru CL, Cainap CI, Anghel R, Dvorkin MV, Gladkov OA, Fadeeva NV, Kuzmin AA, Lipatov ON, Zbarskaya II, Akhmetzyanov FS, Litvinov IV, Afanasyev BV, Cherenkova M, Lioznov D, Lisukov IA, Smirnova YA, Kolomietz S, Halawani H, Goh YT, Drgona L, Chudej J, Matejkova M, Reckova M, Rapoport BL, Szpak WM, Malan DR, Jonas N, Jung CW, Lee DG, Yoon SS, Lopez Jimenez J, Duran Martinez I, Rodriguez Moreno JF, Solano Vercet C, de la Camara R, Batlle Massana M, Yeh SP, Chen CY, Chou HH, Tsai CM, Chiu CH, Siritanaratkul N, Norasetthada L, Sriuranpong V, Seetalarom K, Akan H, Dane F, Ozcan MA, Ozsan GH, Kalayoglu Besisik SF, Cagatay A, Yalcin S, Peniket A, Mullan SR, Dakhil KM, Sivarajan K, Suh JJG, Sehgal A, Marquez F, Gomez EG, Mullane MR, Skinner WL, Behrens RJ, Trevarthe DR, Mazurczak MA, Lambiase EA, Vidal CA, Anac SY, Rodrigues GA, Baltz B, Boccia R, Wertheim MS, Holladay CS, Zenk D, Fusselman W, Wade III JL, Jaslowsk AJ, Keegan J, Robinson MO, Go RS, Farnen J, Amin B, Jurgens D, Risi GF, Beatty PG, Naqvi T, Parshad S, Hansen VL, Ahmed M, Steen PD, Badarinath S, Dekker A, Scouros MA, Young DE, Graydon Harker W, Kendall SD, Citron ML, Chedid S, Posada JG, Gupta MK, Rafiyath S, Buechler-Price J, Sreenivasappa S, Chay CH, Burke JM, Young SE, Mahmood A, Kugler JW, Gerstner G, Fuloria J, Belman ND, Geller R, Nieva J, Whittenberger BP, Wong BMY, Cescon TP, Abesada-Terk G, Guarino MJ, Zweibach A, Ibrahim EN, Takahashi G, Garrison MA, Mowat RB, Choi BS, Oliff IA, Singh J, Guter KA, Ayrons K, Rowland KM, Noga SJ, Rao SB, Columbie A, Nualart MT, Cecchi GR, Campos LT, Mohebtash M, Flores MR, Rothstein-Rubin R, O'Connor BM, Soori G, Knapp M, Miranda FG, Goodgame BW, Kassem M, Belani R, Sharma S, Ortiz T, Sonneborn HL, Markowitz AB, Wilbur D, Meiri E, Koo VS, Jhangiani HS, Wong L, Sanani S, Lawrence SJ, Jones CM, Murray C, Papageorgiou C, Gurtler JS, Ascensao JL, Seetalarom K, Venigalla ML, D'Andrea M, De Las Casas C, Haile DJ, Qazi FU, Santander JL, Thomas MR, Rao VP, Craig M, Garg RJ, Robles R, Lyons RM, Stegemoller RK, Goel S, Garg S, Lowry P, Lynch C, Lash B, Repka T, Baker J, Goueli BS, Campbell TC, Van Echo DA, Lee YJ, Reyes EA, Senecal FM, Donnelly G, Byeff P, Weiss R, Reid T, Roeland E, Goel A, Prow DM, Brandt DS, Kaplan HG, Payne JE, Boeckh MG, Rosen PJ, Mena RR, Khan R, Betts RF, Sharp SA, Morrison VA, Fitz-Patrick D, Congdon J, Erickson N, Abbasi R, Henderson S, Mehdi A, Wos EJ, Rehmus E, Beltzer L, Tamayo RA, Mahmood T, Reboli AC, Moore A, Brown JM, Cruz J, Quick DP, Potz JL, Kotz KW, Hutchins M, Chowhan NM, Devabhaktuni YD, Braly P, Berenguer RA, Shambaugh SC, O'Rourke TJ, Conkright WA, Winkler CF, Addo FEK, Duic JP, High KP, Kutner ME, Collins R, Carrizosa DR, Perry DJ, Kailath E, Rosen N, Sotolongo R, Shoham S, Chen T. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. The Lancet Infectious Diseases 2019; 19:1001-1012. [DOI: 10.1016/s1473-3099(19)30310-x] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Revised: 05/02/2019] [Accepted: 05/03/2019] [Indexed: 12/25/2022]
|
2
|
Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy B, Rowland KM, Smith DA, Berg A, Stella PJ, Loprinzi CL. The use of vitamin E for prevention of chemotherapy-induced peripheral neuropathy: A phase III double-blind, placebo controlled study—N05C3 1. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9532] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9532 Background: Chemotherapy induced peripheral neuropathy (CIPN) continues to be a substantial problem for many cancer patients (pts). Pursuant to promising appearing pilot data, the current study evaluated the use of vitamin E for the prevention of CIPN. Methods: A phase III, randomized, double-blind, placebo controlled study was conducted in pts undergoing therapy with neurotoxic chemotherapy, utilizing twice daily dosing of vitamin E (400mg)/placebo. The primary endpoint was the incidence of grade 2+ sensory neuropathy (SN) toxicity (CTCAE v 3.0) in each treatment arm, analyzed by Chi-square testing. Major eligibility criteria included: planned curative intent adjuvant chemotherapy with neurotoxic chemotherapy, ≥ 18 years of age, ECOG PS of ≤2, no existing peripheral neuropathy or coronary artery disease, no prior treatment with neurotoxic chemotherapy, and no concurrent treatment with neuropathic or opioid pain medication. Planned sample size was 100 patients per arm, to provide 80% power to detect a difference in incidence of grade 2+ SN toxicity from 25% in the placebo group to 10% in the vitamin E group. Results: Two-hundred seven pts were enrolled between 12/01/2006 and 12/14/2007. Cytotoxic agents included taxanes (109), cisplatin (8), carboplatin (2), oxaliplatin (50) or combination (20). Eleven pts canceled prior to starting treatment and there were 7 ineligible pts on study. Thus there were 189 evaluable pts included in the current analysis. In this analysis, there was no difference in the incidence of grade 2+ SN between the 2 arms (vitamin E- 34% [95% CI- 25.0–44.8%] placebo- 29% [20.1–39.4%]; P=0.43). There, likewise, were no significant differences between treatment arms for time to onset of neuropathy (P= 0.72), for chemotherapy dose reductions due to neuropathy (P= 0.21) or patient questionnaire reported neuropathy symptoms. The treatment was well tolerated overall. Conclusions: Vitamin E did not appear to reduce the incidence of sensory neuropathy in the studied group of patients receiving neurotoxic chemotherapy but it appeared to be well tolerated. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. A. Kottschade
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - J. A. Sloan
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - M. A. Mazurczak
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - D. B. Johnson
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - B. Murphy
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - K. M. Rowland
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - D. A. Smith
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - A. Berg
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - P. J. Stella
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| |
Collapse
|
3
|
Traynor AM, Levy DE, Bayer GK, Tate JM, Thomas SP, Mazurczak MA, Graham DL, Kolesar JM, Schiller JH. ECOG 1503: A phase II trial of triapine (NSC#663249) with gemcitabine (T/G) as 2 nd line treatment of non-small cell lung cancer (NSCLC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17151] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17151 Background: Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) is a novel chelator of the ribonucleotide reductase (RR) subunit M2. Triapine was shown to enhance cellular uptake and DNA incorporation of gemcitabine in tumor cell lines. Preclinical evidence suggested that cells with the wild-type (wT) MDR1 gene may have lower intratumoral concentrations of Triapine. Objectives: Primary objective was response rate (RR). Secondary objectives included rate of stable disease (SD), progression free survival (PFS), overall survival (OS), and safety of T/G in the 2nd line treatment of advanced NSCLC. Correlative objectives were to examine the effects of MDR1 polymorphisms, RRM1, RRM2, and p53R2 protein and gene expression, and germline and tumor mutations of p53 on clinical outcomes. Methods: Pts with relapsed NSCLC who failed one prior cytotoxic regimen were eligible; prior gemcitabine was excluded. Treatment: Triapine 105 mg/m2 IV on days 1, 8, and 15 and gemcitabine 1000 mg/m2 on days 1, 8, and 15, of a 28 day cycle. Results: 18 pts enrolled from 11/04–1/05. Stage: IIIB (1 pt); IV (17 pts). PS: 0 (4 pts); 1 (14 pts). Median number of cycles administered: 2. No objective antitumor responses were seen. 5 pts experienced SD (range 7–135 days). Median OS: 5.4 mo (95%CI 3.98, not yet reached); median PFS: 3.2 mo (95%CI 1.7, 6.4); estimated 1 yr OS: 39% (SE 13%). Worst Gr 3/4 toxicities: leucopenia (Gr 3–8 pts; Gr 4–1 pt), neutropenia (Gr 3–8 pts; Gr 4–2 pts), hypoxia (Gr 3–4 pts), vomiting (Gr 3–2 pts). Genotyping for MDR1 polymorphisms C1236T, G2677T, and C3435T was performed on all pts. None of the 5 pts with SD were wTs. Pts with wT MDR1 had increased GI and pulmonary toxicity. Additional correlative data will be available for the meeting. Conclusions: T/G did not demonstrate clinically relevant activity in relapsed NSCLC. Genotyping for MDR1 polymorphisms may predict both efficacy and toxicity. [Table: see text]
Collapse
Affiliation(s)
- A. M. Traynor
- University of Wisconsin Cancer Center, Madison, WI; Dana-Farber Cancer Institute, Boston, MA; Green Bay Oncology, Green Bay, WI; MeritCare Hospital CCOP, Fargo, ND; Illinois Oncology Research Association, Peoria, IL; Sioux Valley Clinic Oncology, Sioux Falls, SD; Carle Cancer Center, Urbana, IL
| | - D. E. Levy
- University of Wisconsin Cancer Center, Madison, WI; Dana-Farber Cancer Institute, Boston, MA; Green Bay Oncology, Green Bay, WI; MeritCare Hospital CCOP, Fargo, ND; Illinois Oncology Research Association, Peoria, IL; Sioux Valley Clinic Oncology, Sioux Falls, SD; Carle Cancer Center, Urbana, IL
| | - G. K. Bayer
- University of Wisconsin Cancer Center, Madison, WI; Dana-Farber Cancer Institute, Boston, MA; Green Bay Oncology, Green Bay, WI; MeritCare Hospital CCOP, Fargo, ND; Illinois Oncology Research Association, Peoria, IL; Sioux Valley Clinic Oncology, Sioux Falls, SD; Carle Cancer Center, Urbana, IL
| | - J. M. Tate
- University of Wisconsin Cancer Center, Madison, WI; Dana-Farber Cancer Institute, Boston, MA; Green Bay Oncology, Green Bay, WI; MeritCare Hospital CCOP, Fargo, ND; Illinois Oncology Research Association, Peoria, IL; Sioux Valley Clinic Oncology, Sioux Falls, SD; Carle Cancer Center, Urbana, IL
| | - S. P. Thomas
- University of Wisconsin Cancer Center, Madison, WI; Dana-Farber Cancer Institute, Boston, MA; Green Bay Oncology, Green Bay, WI; MeritCare Hospital CCOP, Fargo, ND; Illinois Oncology Research Association, Peoria, IL; Sioux Valley Clinic Oncology, Sioux Falls, SD; Carle Cancer Center, Urbana, IL
| | - M. A. Mazurczak
- University of Wisconsin Cancer Center, Madison, WI; Dana-Farber Cancer Institute, Boston, MA; Green Bay Oncology, Green Bay, WI; MeritCare Hospital CCOP, Fargo, ND; Illinois Oncology Research Association, Peoria, IL; Sioux Valley Clinic Oncology, Sioux Falls, SD; Carle Cancer Center, Urbana, IL
| | - D. L. Graham
- University of Wisconsin Cancer Center, Madison, WI; Dana-Farber Cancer Institute, Boston, MA; Green Bay Oncology, Green Bay, WI; MeritCare Hospital CCOP, Fargo, ND; Illinois Oncology Research Association, Peoria, IL; Sioux Valley Clinic Oncology, Sioux Falls, SD; Carle Cancer Center, Urbana, IL
| | - J. M. Kolesar
- University of Wisconsin Cancer Center, Madison, WI; Dana-Farber Cancer Institute, Boston, MA; Green Bay Oncology, Green Bay, WI; MeritCare Hospital CCOP, Fargo, ND; Illinois Oncology Research Association, Peoria, IL; Sioux Valley Clinic Oncology, Sioux Falls, SD; Carle Cancer Center, Urbana, IL
| | - J. H. Schiller
- University of Wisconsin Cancer Center, Madison, WI; Dana-Farber Cancer Institute, Boston, MA; Green Bay Oncology, Green Bay, WI; MeritCare Hospital CCOP, Fargo, ND; Illinois Oncology Research Association, Peoria, IL; Sioux Valley Clinic Oncology, Sioux Falls, SD; Carle Cancer Center, Urbana, IL
| |
Collapse
|